Blair William & Co. IL Has $313.79 Million Stake in Eli Lilly and Company (NYSE:LLY)

Blair William & Co. IL grew its holdings in shares of Eli Lilly and Company (NYSE:LLY) by 4.6% in the second quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm owned 346,588 shares of the company’s stock after acquiring an additional 15,133 shares during the period. Eli Lilly and Company accounts for approximately 1.0% of Blair William & Co. IL’s investment portfolio, making the stock its 22nd biggest holding. Blair William & Co. IL’s holdings in Eli Lilly and Company were worth $313,794,000 at the end of the most recent quarter.

Several other hedge funds have also recently made changes to their positions in LLY. AMJ Financial Wealth Management bought a new stake in shares of Eli Lilly and Company in the 4th quarter valued at $201,000. Aveo Capital Partners LLC boosted its stake in Eli Lilly and Company by 8.2% during the fourth quarter. Aveo Capital Partners LLC now owns 2,020 shares of the company’s stock worth $1,178,000 after acquiring an additional 153 shares in the last quarter. Gryphon Financial Partners LLC grew its holdings in Eli Lilly and Company by 19.4% in the fourth quarter. Gryphon Financial Partners LLC now owns 2,324 shares of the company’s stock worth $1,355,000 after purchasing an additional 377 shares during the period. Hillsdale Investment Management Inc. increased its stake in Eli Lilly and Company by 11.0% in the fourth quarter. Hillsdale Investment Management Inc. now owns 804 shares of the company’s stock valued at $469,000 after purchasing an additional 80 shares in the last quarter. Finally, Sachetta LLC acquired a new position in shares of Eli Lilly and Company during the fourth quarter valued at about $99,000. 82.53% of the stock is owned by institutional investors.

Insider Buying and Selling

In related news, major shareholder Lilly Endowment Inc sold 9,671 shares of the firm’s stock in a transaction dated Thursday, June 20th. The shares were sold at an average price of $902.67, for a total transaction of $8,729,721.57. Following the completion of the sale, the insider now owns 97,574,139 shares in the company, valued at $88,077,248,051.13. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. In the last ninety days, insiders have sold 451,900 shares of company stock valued at $418,732,178. 0.13% of the stock is owned by insiders.

Analyst Ratings Changes

Several analysts have recently commented on LLY shares. Jefferies Financial Group raised their target price on Eli Lilly and Company from $994.00 to $1,015.00 and gave the company a “buy” rating in a research note on Monday, June 24th. Barclays increased their price target on Eli Lilly and Company from $913.00 to $1,025.00 and gave the stock an “overweight” rating in a report on Wednesday, July 10th. Berenberg Bank boosted their price objective on Eli Lilly and Company from $1,000.00 to $1,050.00 and gave the company a “buy” rating in a report on Wednesday, August 14th. BMO Capital Markets upped their target price on Eli Lilly and Company from $1,001.00 to $1,101.00 and gave the stock an “outperform” rating in a research report on Friday, August 9th. Finally, Deutsche Bank Aktiengesellschaft raised shares of Eli Lilly and Company from a “hold” rating to a “buy” rating and lifted their price target for the company from $725.00 to $1,025.00 in a research report on Monday, August 12th. Three equities research analysts have rated the stock with a hold rating and seventeen have assigned a buy rating to the stock. According to MarketBeat, the stock currently has an average rating of “Moderate Buy” and a consensus target price of $977.35.

Eli Lilly and Company Trading Down 1.9 %

NYSE:LLY opened at $906.17 on Wednesday. Eli Lilly and Company has a 52 week low of $516.57 and a 52 week high of $972.53. The firm has a 50-day moving average price of $896.70 and a two-hundred day moving average price of $835.96. The company has a debt-to-equity ratio of 1.74, a quick ratio of 0.87 and a current ratio of 1.11. The firm has a market cap of $861.23 billion, a price-to-earnings ratio of 133.46, a price-to-earnings-growth ratio of 2.79 and a beta of 0.42.

Eli Lilly and Company (NYSE:LLY) last issued its quarterly earnings results on Thursday, August 8th. The company reported $3.92 EPS for the quarter, beating analysts’ consensus estimates of $2.64 by $1.28. The company had revenue of $11.30 billion during the quarter, compared to the consensus estimate of $9.83 billion. Eli Lilly and Company had a return on equity of 67.52% and a net margin of 18.86%. On average, equities analysts expect that Eli Lilly and Company will post 16.49 earnings per share for the current fiscal year.

Eli Lilly and Company Dividend Announcement

The firm also recently announced a quarterly dividend, which was paid on Tuesday, September 10th. Stockholders of record on Thursday, August 15th were paid a dividend of $1.30 per share. This represents a $5.20 dividend on an annualized basis and a dividend yield of 0.57%. The ex-dividend date of this dividend was Thursday, August 15th. Eli Lilly and Company’s payout ratio is 76.58%.

About Eli Lilly and Company

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.